Plain-English translation of NCT06742710 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing liraglutide, a medication approved for weight loss, to see if it can help women with polycystic ovary syndrome (PCOS) who are overweight and struggling to become pregnant. The medication works by helping your body control blood sugar, reduce weight, and lower inflammation—all things that can affect fertility. Researchers believe that by taking this treatment before having an embryo transferred during fertility treatment, women may have better chances of becoming pregnant and having a healthy baby.
PCOS is a common condition that makes it harder for women to become pregnant, and being overweight makes this even more difficult. While this medication has been shown to help with weight loss and hormone balance in women with PCOS, researchers want to confirm through a large study whether using it before fertility treatment actually improves the chances of a successful pregnancy.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to either take the weight-loss medication plus , or just alone, before your embryo transfer procedure. You will take your assigned medications by injection or as directed by the study team, attend regular clinic visits to monitor your weight, blood sugar, and overall health, and then proceed with your fertility treatment. The study will track your pregnancy outcomes and your baby's health to see whether the medication improved your chances of success.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China